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Eﬃcacy of desmopressin in patients with
multiple sclerosis suﬀering from bladder
dysfunction: a meta-analysis
Bladder dysfunction is a very common problem
in patients with multiple sclerosis (MS). Approxi-
mately 90% of MS patients have bladder problems
during the course of the disease, including
increased voiding frequency, urgency problems
and incontinence (1–3).
Bladder problems are very distressing and aﬀect
many important aspects of everyday life, such as
social inconvenience, for example in the work
situation, during a theatre visit, a meeting or other
social occasions. However, the physical and emo-
tional health status of MS patients is also aﬀected
by motor problems and fatigue and the combina-
tion of these symptoms may increase psychological
distress and problems in coping with nocturia,
daytime frequency and incontinence. In addition,
these problems may increase the burden on the
patient’s partner or carer. The reduction of voiding
frequency and incontinence are therefore relevant
therapeutic goals that may improve the patient’s
perceived health status and quality of life. Admin-
istration of desmopressin would appear to be an
eﬀective and well-tolerated method to reduce the
voiding frequency and incontinence in MS patients
with varying neurological disability and handicap-
ping micturition problems. Desmopressin (1-des-
mino-8-d-arginine vasopressin) is a synthetic
analogue of the anti-diuretic hormone vasopressin.
The drug increases the resorption of water in the
collecting tubules of the kidneys. The safety and
eﬃcacy of this drug was shown in patients with
diabetes insipides and nocturnal enuresis (4, 5).
Some studies have evaluated the effect of desmo-
pressin in patients with MS (1, 6–9). The current
review evaluates the safety and efﬁcacy of desmo-
pressin in patients with MS who suffer from both
daytime and nocturnal voiding frequency and from
incontinence.
Materials and methods
A literature search was carried out looking for
studies published between 1990 and 2003 which
evaluated desmopressin in MS patients with blad-
der dysfunction. Electronic databases such as
Medline, Cinahl, Embase, Psychinfo and Picarta
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were employed using the search terms multiple
sclerosis and desmopressin.
The studies had to meet four criteria for inclu-
sion. First, they had to have been published in
English or Dutch. Secondly, the design had to be a
clinical trial or a randomized clinical trial. Thirdly,
only MS patients with bladder dysfunction could
be the subject of evaluation of desmopressin
eﬀectiveness. Finally, the studies had to have only
used one or more of the following outcome
parameters: voiding frequency, incontinence,
urine volume and/or serum sodium level. Only
statistically signiﬁcant diﬀerences in outcome
parameters between treatment with desmopressin
and control conditions were used to evaluate the
eﬀectiveness of treatment by pooling the eﬀect size
(ES) estimates (10). The ES was estimated by
calculating the mean difference between the pla-
cebo and desmopressin groups after the interven-
tion, and divided by the pooled standard deviation
(SD) of the post-treatment outcome measure of the
placebo and desmopressin group (11). Cohen’s
threshold values for interpretation of the magni-
tude of differences between treatment and control
groups were used: trivial effect (ES £ 0.20), small
effect (ES ‡ 0.20 < 0.50), moderate effect
(ES ‡ 0.50 < 0.80) and large effect (ES ‡ 0.80)
(12).
Results
The use of the keywords in the literature search
resulted in 57 publications. After applying the
inclusion and exclusion criteria, the selection
yielded ﬁve studies which were appropriate for a
meta-analysis (1, 6–9) with a randomized double-
blind placebo-controlled, cross-over design. Des-
mopressin was administered both as an oral and
nasal drug during the daytime and at night. The
studies comprised 115 MS patients with increased
frequency of voiding/incontinence episodes. Only
98 patients (85%) were included for statistical
analysis: 70 women (71%) and 28 men (29%) with
a mean age of 49 years (range 24–70). Table 1
summarizes the results of the clinical outcome
parameters which the studies have in common.
Frequency and urine volume
Desmopressin increases the resorption of water
and therefore has a negative eﬀect on the urine
volume, which also has an eﬀect on the voiding
frequency and incontinence. All the studies evalu-
ated mean voiding frequency, either 6 h after
desmopressin during the day (between 8.00 and
14.00 h), or after desmopressin was used at night
(bedtime). A statistically signiﬁcant lower voiding
frequency in the ﬁrst 6–8 h after the administration
of desmopressin was detected in all of the studies.
The mean diﬀerence in the voiding frequency
between the placebo and desmopressin groups
ranged from 0.5 to 0.7 during the day, and from
0.5 to 1.0 during the night. Three studies evaluated
the urine volume in the ﬁrst 6 or 8 h or during the
night after taking the drug. All three studies
detected statistically signiﬁcant diﬀerences in
urine volume between the desmopressin and pla-
cebo groups. Furthermore, two studies evaluated
24-h urine volumes, but no statistically signiﬁcant
diﬀerences between the desmopressin and placebo
groups were detected.
Serum levels
No statistically signiﬁcant diﬀerences were detected
between the placebo and desmopressin groups in
anyof the studieswhich evaluated the levels of serum
sodium. Kinn and Larsson (9) did not present any
Table 1 Effectiveness of desmopressin as a treatment for urgency and incontinence in five experimental studies among patients with multiple sclerosis (statistically
significant differences are printed in bold





















Mean no. of voids in 6 h (SD) 2.4 (0.9) 3.1 (1.4) 2.6 (1.0) 3.1 (1.0) 2.4 (1.0) 3.1 (1.1)
Mean no. of
night-time voids (SD)
1.27 (0.8) 1.74 (0.66) 1.09 (1.10) 2.07 (1.13)
Mean urine volume
in 6 h or night, ml (SD)
341 (134) 502 (201) 246 (99) 342 (166) 3251 440
Mean urine volume
in 24 h, ml (SD)
1372.1
(478.4)
1510.5 (483.2) 1218 (455) 1272 (482)
Mean serum sodium,
mmol/l (SD)
140.2 (4.8) 141.5 (3.2) 139.2 (3.3) 139.7 (3.0) 140 (3.1) 141 (3.2) 139.8 (1.4) 140.5 (1.7)
1According to the authors this difference was statistically significant. However, as no standard deviations were published, no effect size estimates could be calculated.
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statistical information regarding the level of serum
sodium; however, they concluded that blood sample
outcomes remained stable during the study.
Side-effects
Most of the reported side-eﬀects are related to
hyponatraemia. In general these symptoms were
assessed as being mild. Patients (0–8%) reported
ﬂuid retention or side-eﬀects related to ﬂuid
retention. Headache was seen in 3–4% of the
research population. Other mild symptoms repor-
ted included nausea, swollen ankles, abdominal
aches, increased hesitancy, but most of these
symptoms vanished spontaneously.
Patients preference
After pooling the data from the studies, 72% of 81
patients preferred the period in which they were
treated with desmopressin to the period in which
they were treated with a placebo. Fredrikson (7)
found that 68% of patients had a preference for the
active treatment phase, whilst others researchers (6,
8, 9) found 65, 80 and 75%, respectively. Further-
more, Valiquette et al. (1) reported that 82% of the
patients requested a continuation of desmopressin
after the trial. Furthermore, patients included in
their study reported that desmopressin treatment
restored their normal sleep patterns, which resulted
in dramatic improvements in their quality of life (1).
Clinically relevant differences
The problem of testing diﬀerences between placebo
and desmopressin groups with a null hypothesis is
that the outcome has to be suﬃciently diﬀerent
from what would have been expected on the basis
of chance (P < a).
However, statistically signiﬁcant results do not
imply that the eﬀects of each study were important,
as trivial diﬀerences between experimental groups
are likely to be statistically signiﬁcant in large
samples.
Eﬀect size indices were used in order to give
meaning to the magnitude of these statistically
signiﬁcant diﬀerences. These indices standardize
the diﬀerences between mean scores to adjust for
arbitrary units of measurement in order to produce
a measure in standard deviation units rather than
in the units of the original scale. In order to assess
the clinical relevance of the diﬀerences in outcome
between placebo and desmopressin groups, the
results of the selected studies from Table 1 were
aggregated by pooling the ES of each study into a
grand mean ES index.
Table 2 shows the grand mean ES estimates
from the sample values found in the ﬁve studies
which compared the outcome in the placebo and
desmopressin groups (13). The grand total mean
ES show the following estimates of clinical relevant
differences: desmopressin has a moderate effect on
the number of voids during the day or during the
night over a period of 6 h after taking the drug. A
large effect associated with the use of desmopressin
was detected by the mean difference in urine
volume (ml) in 6 h. A small effect was detected in
the mean 24-h urine volume. Serum sodium levels
were combined with plasma osmolality in some
studies and were found to be not signiﬁcantly
affected by desmopressin treatment.
Conclusion/discussion
To our knowledge, only ﬁve studies have evaluated
the eﬀectiveness and safety of desmopressin in
patients with MS in an RCT study design during
the period 1990 and 2003. All studies used self-
assessment of the voiding frequency and side-
eﬀects.
Voiding frequency and/or incontinence is signi-
ﬁcantly decreased in the ﬁrst 6–8 h or at night in
the group of patients receiving desmopressin. This
is probably the most important factor for the
patients. During the night the voiding frequency
determines the extent of a disturbed sleeping
pattern. Correspondingly, urinary volume signiﬁ-
cantly and substantially (ES > 0.80) decreased in
this period. Most patients preferred the treatment
with desmopressin even though the reduction in
voids was small. The question is whether or not
this reduction is clinically relevant. Reported side-
eﬀects mainly correspond with hyponatraemia and
ﬂuid retention. In general, the side-eﬀects were
mild. Hyponatraemia, however, can have serious
consequences. It is, on the one hand, important to
stress the possible risk of hyponatraemia and its
symptoms and to emphasize that it should be used
only once a day. On the other hand, the emphasis
should not be so great that the patient’s compli-
ance is aﬀected negatively as this may be problem-
atic in MS patients with cognitive impairments.
Patients with cardiovascular and renal diseases,
Table 2 Grand total effect size (ES) estimates
Outcome measures Range ES Effect
Mean no. of voids in 6 h 0.50–0.67 0.60 Moderate
Mean no. of night-time voids 0.64–0.88 0.77 Moderate
Mean urine volume in 6 h (ml) 0.71–0.95 0.83 Large
Mean urine volume in 24 h (ml) 0.11–0.29 0.20 Small
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hypertension, diabetes and hepatic diseases should
not be treated (1, 9).
It could be argued that the use of desmopressin
inﬂuences the incidence of urinary tract infections.
The higher urinary concentration may provide less
favourable conditions for bacterial growth. Longer
intervals between voids, however, increase bacter-
ial growth. Two studies evaluated the incidence of
urinary tract infections and found that it ranged
from 6 to 23%.
Most studies refer to indications for administra-
tion of desmopressin in MS patients with lower
urinary tract dysfunction. In general the indica-
tions are advanced urgency and urinary leakage
due to detrusor hyperreﬂexia (6, 7, 9). In fact
desmopressin is a novel approach to the manage-
ment of lower urinary tract dysfunctions in MS.
Well-known measures are the application of ﬂuid
restriction (in order to minimize bladder ﬁlling),
anticholinergic drugs (to relax the bladder muscu-
lature and to increase bladder capacity), and
intermittent self-catheterization (to empty the
bladder at ﬁxed time-intervals). Consequently the
studies vary in the indications for application of
desmopressin as an additional measure to well-
known methods in special situations: 1) in case of
socially handicapping bladder dysfunction or in
case of resistance to other drugs (anticholinergics)
(7); 2) when anticholinergetic therapy is unfavour-
able because of signiﬁcant adverse effects (1) and 3)
to gain symptomatic control of nocturnal urine
production rates (1, 6).
Most studies evaluated the eﬃcacy of 10 or
20 lg of desmopressin. One study was found in
which incrementally increasing doses of 20, 40 and
60 lg were compared (14). This study showed that
doses of >20 lg cannot be recommended, as they
had no immediate advantages over a 20-lg dose in
reducing urinary production or increasing urinary
osmolality. Furthermore, there was a potentially
worrying trend towards hyponatraemia on com-
pleting a 60- lg dose (14).
The studies included in our literature search
evaluated the short-term eﬀect of desmopressin.
Two studies evaluating the long-term eﬀect of
desmopressin were also found. One retrospective
study covered an average follow-up of 2.4 years
(15). A substantial number of the patients (74%)
reported a stable effect of desmopressin.
In another study (16), in which only eight
patients were included, Valiquette et al. reported
a stable effect during a mean period of 13 months
(1). These studies indicate that desmopressin may
be effective over a longer period of time.
Three studies referred to pros and cons of oral
and nasal administration of desmopressin in MS
patients with bladder dysfunction: Kinn and Lars-
son (9) referred to difﬁculties in nasal administra-
tion for patients with muscular and motor
dysfunctions. Eckford et al. (6), on the other
hand, found that despite severely compromised
manual dexterity patients were able to self-admin-
ister the drug. Fredrikson (7) referred to possible
treatment failures in nasal application due to
improper spraying technique and reduced nasal
absorption. Possible disadvantages of oral admin-
istration are the slower onset of action compared
to intranasal application and the oral dose is more
than 10 times the dose used for intranasal admin-
istration (9).
Desmopressin can play a signiﬁcant role in the
health-related functional status of MS patients,
especially those patients with a high frequency
both during daytime, on special occasions and at
night, for an undisturbed sleep. This therapy can
be greatly beneﬁcial in this group of patients,
reducing the number of voids, for example, by
50%. Other therapies are ﬁrst recommended as the
costs are rather high and the clinical relevance is
limited. When prescribing desmopressin, attention
should be paid to hyponatraemia. It is clear that
the long-term eﬀects, eﬀects on urinary tract
infections and the hours of undisturbed sleep
need further investigation.
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